CA3192763A1 - Compounds and compositions as sppl2a inhibitors - Google Patents
Compounds and compositions as sppl2a inhibitorsInfo
- Publication number
- CA3192763A1 CA3192763A1 CA3192763A CA3192763A CA3192763A1 CA 3192763 A1 CA3192763 A1 CA 3192763A1 CA 3192763 A CA3192763 A CA 3192763A CA 3192763 A CA3192763 A CA 3192763A CA 3192763 A1 CA3192763 A1 CA 3192763A1
- Authority
- CA
- Canada
- Prior art keywords
- benzo
- oxo
- pyrazolo
- tetrahydro
- diazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079604P | 2020-09-17 | 2020-09-17 | |
| US63/079,604 | 2020-09-17 | ||
| PCT/IB2021/058398 WO2022058902A1 (en) | 2020-09-17 | 2021-09-15 | Compounds and compositions as sppl2a inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3192763A1 true CA3192763A1 (en) | 2022-03-24 |
Family
ID=77897680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3192763A Pending CA3192763A1 (en) | 2020-09-17 | 2021-09-15 | Compounds and compositions as sppl2a inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20230365571A1 (https=) |
| EP (2) | EP4578451A3 (https=) |
| JP (2) | JP7771172B2 (https=) |
| KR (1) | KR20230069947A (https=) |
| AU (1) | AU2021342783A1 (https=) |
| CA (1) | CA3192763A1 (https=) |
| CL (2) | CL2023000728A1 (https=) |
| CO (1) | CO2023004646A2 (https=) |
| CR (1) | CR20230142A (https=) |
| DK (1) | DK4214210T3 (https=) |
| DO (1) | DOP2023000055A (https=) |
| EC (1) | ECSP23027092A (https=) |
| ES (1) | ES3028668T3 (https=) |
| FI (1) | FI4214210T3 (https=) |
| GE (2) | GEAP202516217A (https=) |
| HR (1) | HRP20250562T1 (https=) |
| HU (1) | HUE071569T2 (https=) |
| IL (1) | IL300953B1 (https=) |
| JO (1) | JOP20230044A1 (https=) |
| LT (1) | LT4214210T (https=) |
| MA (1) | MA61557B1 (https=) |
| MD (1) | MD4214210T2 (https=) |
| MX (1) | MX2023003122A (https=) |
| PE (1) | PE20231099A1 (https=) |
| PL (1) | PL4214210T3 (https=) |
| PT (1) | PT4214210T (https=) |
| RS (1) | RS66874B1 (https=) |
| SI (1) | SI4214210T1 (https=) |
| SM (1) | SMT202500216T1 (https=) |
| WO (1) | WO2022058902A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116947813A (zh) * | 2023-07-06 | 2023-10-27 | 绍兴贝斯美化工股份有限公司 | 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法 |
| US20250263416A1 (en) | 2024-02-15 | 2025-08-21 | Incyte Corporation | SPPL2a INHIBITORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124503C1 (ru) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| GB9612622D0 (en) | 1996-06-17 | 1996-08-21 | Zeneca Ltd | Chemical process |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| JP2008545780A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| WO2015160772A1 (en) | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of tgr5 |
-
2021
- 2021-09-15 MX MX2023003122A patent/MX2023003122A/es unknown
- 2021-09-15 ES ES21773886T patent/ES3028668T3/es active Active
- 2021-09-15 LT LTEPPCT/IB2021/058398T patent/LT4214210T/lt unknown
- 2021-09-15 GE GEAP202516217A patent/GEAP202516217A/en unknown
- 2021-09-15 PL PL21773886.3T patent/PL4214210T3/pl unknown
- 2021-09-15 CR CR20230142A patent/CR20230142A/es unknown
- 2021-09-15 MA MA61557A patent/MA61557B1/fr unknown
- 2021-09-15 HU HUE21773886A patent/HUE071569T2/hu unknown
- 2021-09-15 PT PT217738863T patent/PT4214210T/pt unknown
- 2021-09-15 RS RS20250568A patent/RS66874B1/sr unknown
- 2021-09-15 GE GEAP202116217A patent/GEP20257771B/en unknown
- 2021-09-15 US US18/044,455 patent/US20230365571A1/en active Pending
- 2021-09-15 KR KR1020237011546A patent/KR20230069947A/ko active Pending
- 2021-09-15 PE PE2023001167A patent/PE20231099A1/es unknown
- 2021-09-15 MD MDE20230725T patent/MD4214210T2/ro unknown
- 2021-09-15 FI FIEP21773886.3T patent/FI4214210T3/fi active
- 2021-09-15 EP EP25163259.2A patent/EP4578451A3/en active Pending
- 2021-09-15 JP JP2023517751A patent/JP7771172B2/ja active Active
- 2021-09-15 AU AU2021342783A patent/AU2021342783A1/en active Pending
- 2021-09-15 HR HRP20250562TT patent/HRP20250562T1/hr unknown
- 2021-09-15 IL IL300953A patent/IL300953B1/en unknown
- 2021-09-15 EP EP21773886.3A patent/EP4214210B1/en active Active
- 2021-09-15 SI SI202130298T patent/SI4214210T1/sl unknown
- 2021-09-15 DK DK21773886.3T patent/DK4214210T3/da active
- 2021-09-15 SM SM20250216T patent/SMT202500216T1/it unknown
- 2021-09-15 WO PCT/IB2021/058398 patent/WO2022058902A1/en not_active Ceased
- 2021-09-15 CA CA3192763A patent/CA3192763A1/en active Pending
-
2023
- 2023-02-27 JO JOJO/P/2023/0044A patent/JOP20230044A1/ar unknown
- 2023-03-14 CL CL2023000728A patent/CL2023000728A1/es unknown
- 2023-03-16 DO DO2023000055A patent/DOP2023000055A/es unknown
- 2023-04-14 EC ECSENADI202327092A patent/ECSP23027092A/es unknown
- 2023-04-14 CO CONC2023/0004646A patent/CO2023004646A2/es unknown
-
2024
- 2024-04-29 CL CL2024001312A patent/CL2024001312A1/es unknown
-
2025
- 2025-11-05 JP JP2025186205A patent/JP2026041723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018265130B2 (en) | Thienopyridines and benzothiophenes useful as IRAK4 inhibitors | |
| CN108137586B (zh) | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 | |
| CN104159891B (zh) | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 | |
| CN113072542B (zh) | RORγt抑制剂及其制备方法和用途 | |
| CN108602776A (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
| CN108699032A (zh) | 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途 | |
| US10112944B2 (en) | Heterocyclic compounds useful as inhibitors of TNF | |
| CA2554551A1 (en) | Compositions useful as inhibitors of protein kinases | |
| JP2022553273A (ja) | 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤 | |
| CA3103052A1 (en) | Thiophene derivatives for the treatment of disorders caused by ige | |
| CA3120037A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| AU2018326734B2 (en) | Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists | |
| JP2026041723A (ja) | Ｓｐｐｌ２ａ阻害剤としての化合物及び組成物 | |
| TW201602116A (zh) | 作為β－分泌酶抑制劑之橋接二環胺基噻嗪二氧化物化合物及其使用方法 | |
| CN116615425B (zh) | 作为Sppl2a抑制剂的化合物和组合物 | |
| HK40128790A (en) | Compounds and compositions as sppl2a inhibitors | |
| EA048012B1 (ru) | Соединения и композиции в качестве ингибиторов sppl2a | |
| WO2025133915A1 (en) | Compounds which bind to pnpla3i148m and their use to treat liver diseases | |
| WO2025245351A1 (en) | Substituted aryl sulfonamides and compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240909 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240909 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250908 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250910 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250910 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250910 |